Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy

Experimental Hematology

Volumn 37, Issue 10, 2009, Pages 1216-1229

  Ayello, Janet ^a   van de Ven, Carmella ^a   Cairo, Evan ^a   Hochberg, Jessica ^a   Baxi, Laxmi ^a   Satwani, Prakash ^a   Cairo, Mitchell S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 7; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL COUNT; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; UMBILICAL CORD BLOOD;

CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CRYOPRESERVATION; CULTURE MEDIA, CONDITIONED; CULTURE MEDIA, SERUM-FREE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INFANT, NEWBORN; INTERFERON-GAMMA; INTERLEUKINS; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MONOCYTES; MUROMONAB-CD3; NATURAL KILLER T-CELLS; RECEPTORS, IMMUNOLOGIC;

EID: 70249096604     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.07.009     Document Type: Article

References (50)

1. Cairo M.S., Rocha V., Gluckman E., Hale G., and Wagner J. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 14 Suppl (2008) 44-53
2. Cairo M.S., and Wagner J.E. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 90 (1997) 4665-4678
3. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344 (2001) 1815-1822
4. Bradley M.B., and Cairo M.S. Cord blood immunology and stem cell transplantation. Human Immunol 66 (2005) 431-446
5. van de Ven C., Collins D., Bradley M.B., Morris E., and Cairo M.S. The potential of umbilical cord blood multipotent stem cells for nonhematopoietic tissue and cell regeneration. Exp Hematol 35 (2007) 1753-1765
6. Gluckman E., Rocha V., Arcese W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 32 (2004) 397-407
7. Gluckman E., Rocha V., and Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplantation. Rev Clin Exp Hematol 5 (2001) 87-99
8. Barker J.N., Martin P.L., Coad J.E., et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 7 (2001) 395-399
9. Locatelli F., Rocha V., Chastang C., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 93 (1999) 3662-3671
10. Cairo M.S., Wagner E.L., Fraser J., et al. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 45 (2005) 856-866
11. Fraser J.K., Cairo M.S., Wagner E.L., et al. Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures. J Hematother 7 (1998) 521-561
12. Kurtzberg J., Cairo M.S., Fraser J.K., et al. Results of the cord blood transplantation (COBLT) study unrelated donor banking program. Transfusion 45 (2005) 842-855
13. McNiece I., Kubegov D., Kerzic P., Shpall E.J., and Gross S. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp Hematol 28 (2000) 1181-1186
14. Piacibello W., Sanavio F., Severino A., et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 93 (1999) 3736-3749
15. Robinson S.N., Ng J., Niu T., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 37 (2006) 359-366
16. Azuma H., Yamada Y., Shibuya-Fujiwara N., et al. Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy. Exp Hematol 30 (2002) 346-351
17. Ayello J., van de Ven C., Fortino W., et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant 12 (2006) 608-622
18. Robinson K.L., Ayello J., Hughes R., et al. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Exp Hematol 30 (2002) 245-251
19. Spurr E.E., Wiggins N.E., Marsden K.A., Lowenthal R.M., and Ragg S.J. Cryopreserved human haematopoietic stem cells retain engraftment potential after extended (5-14 years) cryostorage. Cryobiology 44 (2002) 210-217
20. Broxmeyer H.E., Srour E.F., Hangoc G., Cooper S., Anderson S.A., and Bodine D.M. High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 100 (2003) 645-650
21. Gunetti M., Ferrero I., Rustichelli D., et al. Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. Exp Hematol 36 (2008) 235-243
22. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005) 1343-1347
23. Fernandez M.N., Regidor C., Cabrera R., et al. Cord blood transplants: early recovery of neutrophils from co-transplanted sibling haploidentical progenitor cells and lack of engraftment of cultured cord blood cells, as ascertained by analysis of DNA polymorphisms. Bone Marrow Transplant 28 (2001) 355-363
24. Hung G.Y., Chiou T.J., Chang C.Y., Teng H.W., Chen P.M., and Hwanga B. Double-unit unrelated cord blood transplantation for chronic myelogenous leukemia. Int J Hematol 82 (2005) 159-161
25. Pecora A.L., Stiff P., Jennis A., et al. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) using ex vivo expanded and unmanipulated unrelated umbilical cord blood. Bone Marrow Transplant 25 (2000) 797-799
26. Shpall E.J., Quinones R., Giller R., et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 8 (2002) 368-376
27. Rubinstein P., Dobrila L., Rosenfield R.E., et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 92 (1995) 10119-10122
28. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 22 (2001) 633-640
29. Lima M., Teixeira M.A., Queiros M.L., et al. Immunophenotypic characterization of normal blood CD56+lo versus CD56+hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood cells Mol Dis 27 (2001) 731-743
30. Penack O., Gentilini C., Fischer L., et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19 (2005) 835-840
31. Alter G., Malenfant J.M., Delabre R.M., et al. Increased natural killer cell activity in viremic HIV-1 infection. J Immunol 173 (2004) 5305-5311
32. Russell J.H., and Ley T.J. Lymphocyte-mediated cytotoxicity. Ann Rev Immunol 20 (2002) 323-370
33. Alter G., Malenfant J.M., and Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294 (2004) 15-22
34. Aste-Amezaga M., D'Andrea A., Kubin M., and Trinchieri G. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol 156 (1994) 480-492
35. Satwani P., Ayello J., Ven C., et al. Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function. Br J Haematol 130 (2005) 284-292
36. Wei Y., Huang Y., Zhang Y., et al. Ex vivo expansion of CD34+ and T and NK cells from umbilical cord blood for leukemic BALB/C nude mouse transplantation. Int J Hematol 87 (2008) 217-224
37. Farag S.S., and Caligiuri M.A. Human natural killer cell development and biology. Blood Rev 20 (2006) 123-137
38. Wang Y., Xu H., Zheng X., Wei H., Sun R., and Tian Z. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 4 (2007) 377-382
39. Moretta A., Bottino C., Vitale M., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol 19 (2001) 197-223
40. Katz G., Gazit R., Arnon T.I., et al. MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 173 (2004) 1819-1825
41. Lin S.J., Wang L.Y., Huang Y.J., and Kuo M.L. Effect of interleukin (IL)-12 and IL-15 on apoptosis and proliferation of umbilical cord blood mononuclear cells. Bone Marrow Transplant 28 (2001) 439-445
42. Bessoles S., Fouret F., Dudal S., Besra G.S., Sanchez F., and Lafont V. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of pro- and anti-inflammatory cytokines. J Leuk Biol 84 (2008) 224-233
43. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 21 (2000) 573-583
44. Van Kaer L., and Joyce S. Innate immunity: NKT cells in the spotlight. Curr Biol 15 (2005) R429-R431
45. Lanier L.L. On guard-activating NK cell receptors. Nat Immunol 2 (2001) 23-27
46. Bauer S., Groh V., Wu J., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
47. Speiser D.E., Pittet M.J., Valmori D., et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 190 (1999) 775-782
48. Gao J.X., Liu X., Wen J., et al. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 102 (2003) 4456-4463
49. Gapin L., Matsuda J.L., Surh C.D., and Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2 (2001) 971-978
50. Zeng D., Lewis D., Dejbakhsh-Jones S., et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 (1999) 1073-1081